questionsmedicales.fr
Phénomènes génétiques
Structures génétiques
Génome
Composants de génome
Gènes
Composants de gène
Régions non traduites
Régions 3' non traduites
Régions 3' non traduites : Questions médicales fréquentes
Termes MeSH sélectionnés :
Substance-Related Disorders
Diagnostic
5
Séquençage de l'ARN
Analyse bioinformatique
Électrophorèse
ARN messager
Mutations génétiques
Séquençage ciblé
Stabilité de l'ARN
Expression génique
Symptômes
5
Anomalies génétiques
Symptômes cliniques
Maladies génétiques
Symptômes
Réponse au traitement
Expression génique
Syndromes génétiques
Mutations
Prévention
5
Dépistage génétique
Prévention des maladies
Mode de vie sain
Tests génétiques
Antécédents familiaux
Risques génétiques
Programmes de prévention
Sensibilisation
Mode de vie
Expression génique
Traitements
5
Thérapie génique
Traitement médicamenteux
Thérapies ciblées
Expression génique
Modification génétique
Recherche médicale
Régulation génique
Traitements
Médicaments
Recherche pharmacologique
Complications
5
Complications médicales
Troubles génétiques
Cancers
Altérations génétiques
Troubles neurologiques
Mutations génétiques
Facteurs de risque
5
Facteurs de risque
Antécédents familiaux
Facteurs environnementaux
Expression génique
Habitudes de vie
Tabagisme
Mutations
Régions codantes
Tests génétiques
Évaluation des risques
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Régions 3' non traduites : Questions médicales les plus fréquentes",
"headline": "Régions 3' non traduites : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Régions 3' non traduites : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-03-30",
"dateModified": "2025-03-25",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Régions 3' non traduites"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Régions non traduites",
"url": "https://questionsmedicales.fr/mesh/D020506",
"about": {
"@type": "MedicalCondition",
"name": "Régions non traduites",
"code": {
"@type": "MedicalCode",
"code": "D020506",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "G05.360.340.024.340.137.910"
}
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Éléments riches en AU",
"alternateName": "AU Rich Elements",
"url": "https://questionsmedicales.fr/mesh/D063307",
"about": {
"@type": "MedicalCondition",
"name": "Éléments riches en AU",
"code": {
"@type": "MedicalCode",
"code": "D063307",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "G05.360.340.024.340.137.910.880.500"
}
}
}
],
"about": {
"@type": "MedicalCondition",
"name": "Régions 3' non traduites",
"alternateName": "3' Untranslated Regions",
"code": {
"@type": "MedicalCode",
"code": "D020413",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Fan Jiang",
"url": "https://questionsmedicales.fr/author/Fan%20Jiang",
"affiliation": {
"@type": "Organization",
"name": "Prenatal Diagnostic Center, Guangzhou Women and Children's Medical Center, Guangzhou Medical University, Guangzhou, People's Republic of China."
}
},
{
"@type": "Person",
"name": "Dong-Zhi Li",
"url": "https://questionsmedicales.fr/author/Dong-Zhi%20Li",
"affiliation": {
"@type": "Organization",
"name": "Prenatal Diagnostic Center, Guangzhou Women and Children's Medical Center, Guangzhou Medical University, Guangzhou, People's Republic of China."
}
},
{
"@type": "Person",
"name": "Kevin Struhl",
"url": "https://questionsmedicales.fr/author/Kevin%20Struhl",
"affiliation": {
"@type": "Organization",
"name": "Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, Massachusetts, USA."
}
},
{
"@type": "Person",
"name": "Raffaella Liccardo",
"url": "https://questionsmedicales.fr/author/Raffaella%20Liccardo",
"affiliation": {
"@type": "Organization",
"name": "Dipartimento di Medicina Molecolare e Biotecnologie Mediche, Università di Napoli Federico II, 80131 Naples, Italy."
}
},
{
"@type": "Person",
"name": "Marina De Rosa",
"url": "https://questionsmedicales.fr/author/Marina%20De%20Rosa",
"affiliation": {
"@type": "Organization",
"name": "Dipartimento di Medicina Molecolare e Biotecnologie Mediche, Università di Napoli Federico II, 80131 Naples, Italy."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Family members' experiences of caring for a relative with substance-induced psychosis disorder.",
"datePublished": "2022-11-21",
"url": "https://questionsmedicales.fr/article/36453821",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.4102/curationis.v45i1.2348"
}
},
{
"@type": "ScholarlyArticle",
"name": "COVID-19-Related Death in Patients with Alcohol or Substance Use Disorders.",
"datePublished": "2022-11-30",
"url": "https://questionsmedicales.fr/article/36450270",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1159/000527542"
}
},
{
"@type": "ScholarlyArticle",
"name": "Substance Use Disorder.",
"datePublished": "2023-08-05",
"url": "https://questionsmedicales.fr/article/37977753",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.emc.2023.06.023"
}
},
{
"@type": "ScholarlyArticle",
"name": "Provision of health care services related to substance use disorder in southern U.S. jails.",
"datePublished": "2023-12-05",
"url": "https://questionsmedicales.fr/article/38061634",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.josat.2023.209234"
}
},
{
"@type": "ScholarlyArticle",
"name": "Substance Use Disorder-Related Deaths and Maternal Mortality in New Mexico, 2015-2019.",
"datePublished": "2023-06-12",
"url": "https://questionsmedicales.fr/article/37306823",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1007/s10995-023-03691-8"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Phénomènes génétiques",
"item": "https://questionsmedicales.fr/mesh/D055614"
},
{
"@type": "ListItem",
"position": 3,
"name": "Structures génétiques",
"item": "https://questionsmedicales.fr/mesh/D040342"
},
{
"@type": "ListItem",
"position": 4,
"name": "Génome",
"item": "https://questionsmedicales.fr/mesh/D016678"
},
{
"@type": "ListItem",
"position": 5,
"name": "Composants de génome",
"item": "https://questionsmedicales.fr/mesh/D040481"
},
{
"@type": "ListItem",
"position": 6,
"name": "Gènes",
"item": "https://questionsmedicales.fr/mesh/D005796"
},
{
"@type": "ListItem",
"position": 7,
"name": "Composants de gène",
"item": "https://questionsmedicales.fr/mesh/D040461"
},
{
"@type": "ListItem",
"position": 8,
"name": "Régions non traduites",
"item": "https://questionsmedicales.fr/mesh/D020506"
},
{
"@type": "ListItem",
"position": 9,
"name": "Régions 3' non traduites",
"item": "https://questionsmedicales.fr/mesh/D020413"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Régions 3' non traduites - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Régions 3' non traduites",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-03",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Régions 3' non traduites",
"description": "Comment identifier les 3' UTR dans un gène ?\nQuels tests sont utilisés pour étudier les 3' UTR ?\nLes 3' UTR sont-ils visibles sur des électrophorèses ?\nPeut-on détecter des mutations dans les 3' UTR ?\nQuel rôle jouent les 3' UTR dans le diagnostic ?",
"url": "https://questionsmedicales.fr/mesh/D020413?mesh_terms=Substance-Related+Disorders#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Régions 3' non traduites",
"description": "Les 3' UTR sont-ils associés à des symptômes cliniques ?\nQuels symptômes peuvent résulter de mutations dans les 3' UTR ?\nLes 3' UTR affectent-ils la réponse aux traitements ?\nY a-t-il des symptômes spécifiques liés aux 3' UTR ?\nLes 3' UTR peuvent-ils être impliqués dans des syndromes ?",
"url": "https://questionsmedicales.fr/mesh/D020413?mesh_terms=Substance-Related+Disorders#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Régions 3' non traduites",
"description": "Peut-on prévenir les maladies liées aux 3' UTR ?\nQuels conseils pour réduire les risques liés aux 3' UTR ?\nLes antécédents familiaux influencent-ils la prévention ?\nY a-t-il des programmes de prévention pour les 3' UTR ?\nComment le mode de vie affecte-t-il les 3' UTR ?",
"url": "https://questionsmedicales.fr/mesh/D020413?mesh_terms=Substance-Related+Disorders#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Régions 3' non traduites",
"description": "Comment traiter les maladies liées aux 3' UTR ?\nLes thérapies ciblées affectent-elles les 3' UTR ?\nPeut-on modifier les 3' UTR pour traiter des maladies ?\nLes traitements peuvent-ils influencer les 3' UTR ?\nY a-t-il des médicaments ciblant les 3' UTR ?",
"url": "https://questionsmedicales.fr/mesh/D020413?mesh_terms=Substance-Related+Disorders#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Régions 3' non traduites",
"description": "Quelles complications peuvent survenir avec les 3' UTR ?\nLes 3' UTR sont-ils liés à des cancers ?\nComment les 3' UTR affectent-ils la santé ?\nLes complications des 3' UTR sont-elles héréditaires ?\nY a-t-il des complications neurologiques liées aux 3' UTR ?",
"url": "https://questionsmedicales.fr/mesh/D020413?mesh_terms=Substance-Related+Disorders#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Régions 3' non traduites",
"description": "Quels facteurs de risque sont associés aux 3' UTR ?\nL'environnement influence-t-il les 3' UTR ?\nLes habitudes de vie impactent-elles les 3' UTR ?\nLes mutations dans les 3' UTR sont-elles fréquentes ?\nY a-t-il des tests pour évaluer les risques liés aux 3' UTR ?",
"url": "https://questionsmedicales.fr/mesh/D020413?mesh_terms=Substance-Related+Disorders#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment identifier les 3' UTR dans un gène ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les 3' UTR peuvent être identifiés par séquençage d'ARN et analyses bioinformatiques."
}
},
{
"@type": "Question",
"name": "Quels tests sont utilisés pour étudier les 3' UTR ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les tests incluent le RT-PCR et les analyses de microarrays pour évaluer l'expression."
}
},
{
"@type": "Question",
"name": "Les 3' UTR sont-ils visibles sur des électrophorèses ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Non, les 3' UTR ne sont pas visibles directement sur les gels d'électrophorèse."
}
},
{
"@type": "Question",
"name": "Peut-on détecter des mutations dans les 3' UTR ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des mutations dans les 3' UTR peuvent être détectées par séquençage ciblé."
}
},
{
"@type": "Question",
"name": "Quel rôle jouent les 3' UTR dans le diagnostic ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Ils peuvent influencer la stabilité de l'ARN et l'expression des gènes, affectant le diagnostic."
}
},
{
"@type": "Question",
"name": "Les 3' UTR sont-ils associés à des symptômes cliniques ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Indirectement, des anomalies dans les 3' UTR peuvent entraîner des symptômes par régulation génique."
}
},
{
"@type": "Question",
"name": "Quels symptômes peuvent résulter de mutations dans les 3' UTR ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des mutations peuvent causer des maladies génétiques, entraînant divers symptômes."
}
},
{
"@type": "Question",
"name": "Les 3' UTR affectent-ils la réponse aux traitements ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, ils peuvent influencer la réponse aux traitements en modifiant l'expression des gènes."
}
},
{
"@type": "Question",
"name": "Y a-t-il des symptômes spécifiques liés aux 3' UTR ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Non, les symptômes sont généralement liés à des maladies spécifiques, pas aux 3' UTR eux-mêmes."
}
},
{
"@type": "Question",
"name": "Les 3' UTR peuvent-ils être impliqués dans des syndromes ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des syndromes génétiques peuvent être associés à des mutations dans les 3' UTR."
}
},
{
"@type": "Question",
"name": "Peut-on prévenir les maladies liées aux 3' UTR ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "La prévention est difficile, mais un dépistage génétique peut aider à identifier les risques."
}
},
{
"@type": "Question",
"name": "Quels conseils pour réduire les risques liés aux 3' UTR ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Adopter un mode de vie sain et se soumettre à des tests génétiques si nécessaire."
}
},
{
"@type": "Question",
"name": "Les antécédents familiaux influencent-ils la prévention ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des antécédents familiaux de maladies génétiques peuvent augmenter le risque."
}
},
{
"@type": "Question",
"name": "Y a-t-il des programmes de prévention pour les 3' UTR ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des programmes de sensibilisation et de dépistage génétique existent pour certaines maladies."
}
},
{
"@type": "Question",
"name": "Comment le mode de vie affecte-t-il les 3' UTR ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Un mode de vie sain peut influencer l'expression génique, y compris celle des 3' UTR."
}
},
{
"@type": "Question",
"name": "Comment traiter les maladies liées aux 3' UTR ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le traitement dépend de la maladie sous-jacente, souvent par thérapies géniques ou médicamenteuses."
}
},
{
"@type": "Question",
"name": "Les thérapies ciblées affectent-elles les 3' UTR ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certaines thérapies ciblées peuvent moduler l'expression des gènes via les 3' UTR."
}
},
{
"@type": "Question",
"name": "Peut-on modifier les 3' UTR pour traiter des maladies ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des approches de modification des 3' UTR sont en recherche pour traiter certaines maladies."
}
},
{
"@type": "Question",
"name": "Les traitements peuvent-ils influencer les 3' UTR ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certains traitements peuvent affecter la régulation des 3' UTR et l'expression génique."
}
},
{
"@type": "Question",
"name": "Y a-t-il des médicaments ciblant les 3' UTR ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Actuellement, peu de médicaments ciblent spécifiquement les 3' UTR, mais la recherche progresse."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir avec les 3' UTR ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des complications peuvent inclure des maladies génétiques et des troubles de l'expression génique."
}
},
{
"@type": "Question",
"name": "Les 3' UTR sont-ils liés à des cancers ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des altérations dans les 3' UTR peuvent être associées à certains types de cancers."
}
},
{
"@type": "Question",
"name": "Comment les 3' UTR affectent-ils la santé ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Ils régulent l'expression des gènes, et des anomalies peuvent entraîner des problèmes de santé."
}
},
{
"@type": "Question",
"name": "Les complications des 3' UTR sont-elles héréditaires ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines complications peuvent être héréditaires, selon les mutations présentes dans les 3' UTR."
}
},
{
"@type": "Question",
"name": "Y a-t-il des complications neurologiques liées aux 3' UTR ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certaines mutations dans les 3' UTR peuvent être associées à des troubles neurologiques."
}
},
{
"@type": "Question",
"name": "Quels facteurs de risque sont associés aux 3' UTR ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les facteurs incluent des antécédents familiaux, des mutations génétiques et des environnements spécifiques."
}
},
{
"@type": "Question",
"name": "L'environnement influence-t-il les 3' UTR ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des facteurs environnementaux peuvent affecter l'expression des gènes régulés par les 3' UTR."
}
},
{
"@type": "Question",
"name": "Les habitudes de vie impactent-elles les 3' UTR ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines habitudes de vie, comme le tabagisme, peuvent influencer l'expression des 3' UTR."
}
},
{
"@type": "Question",
"name": "Les mutations dans les 3' UTR sont-elles fréquentes ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les mutations dans les 3' UTR sont moins fréquentes que dans les régions codantes, mais significatives."
}
},
{
"@type": "Question",
"name": "Y a-t-il des tests pour évaluer les risques liés aux 3' UTR ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des tests génétiques peuvent évaluer les risques associés aux mutations dans les 3' UTR."
}
}
]
}
]
}
Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale
Validation scientifique effectuée le 25/03/2025
Contenu vérifié selon les dernières recommandations médicales
2 publications dans cette catégorie
Affiliations :
Prenatal Diagnostic Center, Guangzhou Women and Children's Medical Center, Guangzhou Medical University, Guangzhou, People's Republic of China.
Publications dans "Régions 3' non traduites" :
2 publications dans cette catégorie
Affiliations :
Prenatal Diagnostic Center, Guangzhou Women and Children's Medical Center, Guangzhou Medical University, Guangzhou, People's Republic of China.
Publications dans "Régions 3' non traduites" :
2 publications dans cette catégorie
Affiliations :
Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, Massachusetts, USA.
Publications dans "Régions 3' non traduites" :
2 publications dans cette catégorie
Affiliations :
Dipartimento di Medicina Molecolare e Biotecnologie Mediche, Università di Napoli Federico II, 80131 Naples, Italy.
Publications dans "Régions 3' non traduites" :
2 publications dans cette catégorie
Affiliations :
Dipartimento di Medicina Molecolare e Biotecnologie Mediche, Università di Napoli Federico II, 80131 Naples, Italy.
Publications dans "Régions 3' non traduites" :
2 publications dans cette catégorie
Affiliations :
Dipartimento di Medicina Molecolare e Biotecnologie Mediche, Università di Napoli Federico II, 80131 Naples, Italy.
Publications dans "Régions 3' non traduites" :
2 publications dans cette catégorie
Affiliations :
Dipartimento di Medicina Molecolare e Biotecnologie Mediche, Università di Napoli Federico II, 80131 Naples, Italy.
Publications dans "Régions 3' non traduites" :
2 publications dans cette catégorie
Affiliations :
Department of Animal Center, The Fourth Hospital of Hebei Medical University, Shijiazhuang, P.R. China.
Publications dans "Régions 3' non traduites" :
2 publications dans cette catégorie
Affiliations :
Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical Schoolgrid.471403.5, Boston, Massachusetts, USA.
Publications dans "Régions 3' non traduites" :
2 publications dans cette catégorie
Affiliations :
Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical Schoolgrid.471403.5, Boston, Massachusetts, USA.
Publications dans "Régions 3' non traduites" :
2 publications dans cette catégorie
Affiliations :
Department of Pathology, Bethune International Peace Hospital, Shijiazhuang, Hebei 050082, P.R. China.
Publications dans "Régions 3' non traduites" :
2 publications dans cette catégorie
Affiliations :
UT Southwestern Medical Center, Departments of Pharmacology and Biochemistry, Dallas, TX 75205, USA.
Publications dans "Régions 3' non traduites" :
2 publications dans cette catégorie
Affiliations :
Molecular and Cellular Biology, University of Washington, Seattle, WA 98195, USA; Division of Human Biology, Fred Hutchinson Cancer Research Center, Seattle, WA, 98109, USA.
Publications dans "Régions 3' non traduites" :
2 publications dans cette catégorie
Affiliations :
Molecular and Cellular Biology, University of Washington, Seattle, WA 98195, USA; Division of Human Biology, Fred Hutchinson Cancer Research Center, Seattle, WA, 98109, USA; School of Medicine and Genome Sciences, University of Washington, Seattle, WA 98195, USA. Electronic address: ahsieh@fredhutch.org.
Publications dans "Régions 3' non traduites" :
2 publications dans cette catégorie
Affiliations :
Department of Chemistry and Biochemistry, Duquesne University, Pittsburgh, Pennsylvania 15282, United States.
Publications dans "Régions 3' non traduites" :
2 publications dans cette catégorie
Affiliations :
Department of Chemistry and Biochemistry, Duquesne University, Pittsburgh, Pennsylvania 15282, United States.
Publications dans "Régions 3' non traduites" :
2 publications dans cette catégorie
Affiliations :
Department of Chemistry and Biochemistry, Duquesne University, Pittsburgh, Pennsylvania 15282, United States.
Publications dans "Régions 3' non traduites" :
2 publications dans cette catégorie
Affiliations :
Key Laboratory of Cardiovascular and Cerebrovascular Medicine, School of Pharmacy, Nanjing Medical University, Nanjing, China.
Publications dans "Régions 3' non traduites" :
2 publications dans cette catégorie
Affiliations :
Eye Center of Xiangya Hospital, Hunan Key Laboratory of Ophthalmology, Central South University, Changsha, China.
Publications dans "Régions 3' non traduites" :
2 publications dans cette catégorie
Affiliations :
Key Laboratory of Cardiovascular and Cerebrovascular Medicine, School of Pharmacy, Nanjing Medical University, Nanjing, China.
Publications dans "Régions 3' non traduites" :
When there is a lack of resources in the community to support deinstitutionalisation, family members of a relative diagnosed with substance-induced psychosis disorder (SIPD) are the most affected and ...
To explore and describe family members' experiences caring for a relative with SIPD....
The study employed a qualitative research design using interpretative phenomenological analysis as the research method. Telephonic interviews were conducted and analysed. Eight family members were sel...
The analysis of data led to the emergence of the following themes: family members experienced caring for a relative with SIPD as a destabilising responsibility; they experienced acceptance and support...
The study's findings highlighted the family members' experiences of caring for a relative with SIPD and the role of the family, community and government structures in caring for an individual with SIP...
People with substance or alcohol use disorders (SUDs/AUDs) are likely to be more vulnerable to COVID-19 infection than the general population, but the evidence of COVID-19-related mortality in these p...
The aim of the study was to verify whether patients with AUD and SUD have a higher mortality rate for COVID-19-related mortality compared to the general population....
We performed a follow-up study to assess mortality in 2020 in a cohort of patients diagnosed for the first time with AUDs or SUDs at the Public Health Services in the metropolitan area of Bologna (Nor...
SUDs/AUDs patients present an excess mortality with respect to the general population for all causes of death and for COVID-19-related mortality....
Our data support the need for prevention strategies in SUDs/AUDs patients such as vaccinations....
Substance use disorders (SUDs) present a challenge in the emergency department (ED) setting. This article provides an overview of SUDs, their clinical assessment, legal considerations in drug testing,...
The U.S. jail population has more than tripled since the 1980s, and today, one out of every three incarcerated individuals is being held in a county or city jail. Substance use disorders (SUD) are ove...
We conducted a thematic analysis of qualitative data from 34 interviews conducted with 38 personnel from a purposive sample of jails that varied in size and rurality within a five-state study area. Th...
Interviewees described wide variability in both availability and comprehensiveness of SUD-related health care services. Most adhered to federal guidance for supervising withdrawal from alcohol and ben...
This study identified several areas where jails could improve SUD-related health care services. Many of the barriers to improvement-organizational buy-in, cost/budgeting, staffing, logistics-were not ...
In recent decades, maternal mortality has increased across the U.S. Experiences of pregnant and postpartum people with Substance Use Disorder (SUD)-related deaths have not been previously evaluated in...
We conducted an analysis of pregnancy-associated deaths to assess the association between demographics, pregnancy factors, circumstances surrounding death, treatment of mental health conditions, and e...
People with SUD-related deaths were more likely to die 43-365 days postpartum (81% vs. 45%, p-value = 0.002), have had a primary cause of death of mental health conditions (47% vs 10%, p < 0.001), hav...
Providers, health departments, and community organizations must prioritize supporting people using substances during and after pregnancy to prevent death and improve quality of life for pregnant and p...
This longitudinal study identified profiles of patients with substance-related disorders (SRD) who did or did not drop out of specialized addiction treatment, integrating various patterns of outpatien...
Substance use disorder (SUD) is among the leading causes of premature morbidity and mortality and imposes significant health, economic, and social burdens. Gender differences have been found in the de...
The population of elderly in the United States with substance use disorders (SUDs) is growing appreciably. SUDs among the elderly are often associated with poor outcomes and are frequently underdiagno...
Recognizing the specific factors in relapse disorders related to each substance can help improve treatment methods and adopt more effective preventive strategies. This study aimed to compare the situa...
This study was a cross-section type....
The study participants were 150 clients with SRDs and 150 with opiate-related disorders. Samples were selected using two stages random sampling method. Data were collected through a demographic questi...
The mean score of IDTS in the two groups was significantly different (X̄...
This study reveals that despite some similarities, relapse-related situational factors in opiates and stimulants differ. Some situational factors, such as social pressure and coping with unpleasant em...
Despite significant negative outcomes, the co-occurrence of personality disorders (PDs) and substance use disorders (SUDs) continues to be underrecognized, and the mechanisms contributing to this co-o...
The prevalence of co-occurring PD-SUD is generally high, with estimates ranging depending on the type of PD and SUD, the population assessed, and the sampling methods and measures used. Current theore...